Where Will Novavax Be in 1 Year?

At the start of 2020, Novavax (NASDAQ:NVAX) shares were trading at $3.98, and the idea of a commercialized product seemed far off. Then two elements sent the shares into the stratosphere and spurred hope for not one -- but two -- marketed products in the near term. The company said its flu vaccine candidate met all primary endpoints in a pivotal trial. At the same time, Novavax began developing a coronavirus vaccine.

The stock has skyrocketed more than 2,900% winning the title of this year's top performer -- over all companies in all industries. Looking ahead, we might ask ourselves where this biotech-on-the-move may be a year from now. Will this year's work begin to bear fruit? Let's consider what Novavax has accomplished so far and what's next on the agenda.